Strong demand for high-quality, affordable generics is expected to continue growing as governments manage their healthcare budgets in the face of increased pressures. We are strategically positioned to capture significant opportunities in this dynamic market environment.
Our business model
Our diversified business model enables us to respond to the many opportunities and challenges we face, while delivering value for our patients, employees, shareholders and wider communities.
Our strategy
Our strategy is to deliver high-quality and affordable generic and branded generic medicines to patients.
Measuring our success
We are delivering our strategy through our key strategic priorities and measuring our performance with relevant key performance indicators (KPIs).
Why invest
With our unique and established capabilities and strategy for growth, we offer a clear proposition to investors.
Related news
AGM trading update
18 May 2018
Patron of The Prince’s Trust
19 March 2018
Hikma announces global partnership with Direct Relief
15 March 2018